Want to see OLMA full AI Analyst Report?
OLMA Stock Chart & Stats
$16.82
$0.55(10.50%)
At close: 4:00 PM EST
$16.82
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$4.37 - $36.26
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.84M
Market Cap
$1.07B
Enterprise Value$772.97M
Total Cash (Recent Filing)$505.35M
Total Debt (Recent Filing)$956.00K
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 11, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding87,347,470
10 Day Avg. Volume2,014,664
30 Day Avg. Volume1,838,140
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.53K
Enterprise Value/Ebitda-4.19
Forecast
1Y Price Target
$38.14Price Target Upside126.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.22
Revenue Forecast (FY)$2.25M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt-to-equity and a growing equity base provide durable financing flexibility, lowering refinancing risk and enabling multi-year clinical programs. This structural strength supports trial funding or partnerable assets, though it does not eliminate future financing needs if commercialization is delayed.
Strategic Collaboration With BayerA clinical collaboration with a major pharma provides validation, access to a marketed agent for combos, and shared data/IP terms that may de-risk development. Structurally this expands Olema's addressable indications and strengthens its ability to pursue partnership-led development and commercialization strategies.
Early Clinical Efficacy And Tolerability (OP-3136)Consistent tolerability, target engagement, and objective responses in heavily pretreated patients materially reduce clinical risk for OP-3136. Durable early signals support advancement into combination studies and potential registration paths, increasing likelihood of future partnership or standalone value capture.
Bears Say
High And Rising Cash BurnSubstantial and worsening negative operating and free cash flow imply persistent funding needs over the coming months. This structural cash consumption increases the probability of capital raises, restricts discretionary investment, and can delay programs if financing terms are unfavorable.
Pre-revenue Business ModelWith no commercial revenue, the company’s viability depends on clinical success, partnerships, or financings. This structural revenue gap means cash runway and program continuity hinge on trial outcomes and external funding rather than internal cash generation, increasing execution risk.
Dilution Risk And Negative Returns On EquityMaterial cumulative losses and negative ROE indicate shareholder value erosion and make future equity raises likely to fund operations. Structurally, recurring dilution can compress long-term investor returns unless offset by major clinical or commercial milestones.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals, Inc.’s price range in the past 12 months?
Olema Pharmaceuticals, Inc. lowest stock price was $4.37 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals, Inc.’s market cap?
Olema Pharmaceuticals, Inc.’s market cap is $1.07B.
When is Olema Pharmaceuticals, Inc.’s upcoming earnings report date?
Olema Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Olema Pharmaceuticals, Inc.’s earnings last quarter?
Olema Pharmaceuticals, Inc. released its earnings results on May 12, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.531 by $0.011.
Is Olema Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Olema Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Olema Pharmaceuticals, Inc. pay dividends?
Olema Pharmaceuticals, Inc. does not currently pay dividends.
What is Olema Pharmaceuticals, Inc.’s EPS estimate?
Olema Pharmaceuticals, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Olema Pharmaceuticals, Inc. have?
Olema Pharmaceuticals, Inc. has 87,347,470 shares outstanding.
What happened to Olema Pharmaceuticals, Inc.’s price movement after its last earnings report?
Olema Pharmaceuticals, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.531. Following the earnings report the stock price went down -5.989%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.14 (126.77% Upside)
$38.14 (126.77% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
146.09%
12-Months-Change
Fundamentals
Return on Equity
-45.95%
Trailing 12-Months
Asset Growth
29.54%
Trailing 12-Months
Company Description
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
OLMA Stock 12 Month Forecast
Average Price Target
$38.14
▲(126.77% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
10.22% Insiders
21.23% Mutual Funds
0.60% Other Institutional Investors
53.47% Public Companies and Individual Investors